Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Johnson and Johnson (NYSE: JNJ - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-seven research firms that are presently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has assigned a strong
JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU
Johnson & Johnson seeks EMA nod to expand Tecvayli monotherapy use in earlier-line RRMM, backed by phase III MajesTEC-9 data showing strong survival gains.
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
J&J gains EU approval to expand Akeega use to treat patients with BRCA-mutated metastatic hormone-sensitive prostate cancer.
Dividend Aristocrats in a Shaky Market: KO, PG, JNJ, and 2 Others Built to Last
The market's fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month.
Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $239.63, denoting a -2.31% move from the preceding trading day.
Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action
Two Johnson & Johnson units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they were overcharged for the pulmonary hypertension drug Tracleer.
Johnson & Johnson launches website for direct-to-consumer sales
Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either don't have insurance or pay for their drugs out of pocket.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
JNJ's immunology and neuroscience units are driving growth, with Tremfya, Caplyta and Spravato offsetting Stelara's LOE hit.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ) closed the most recent trading day at $248.43, moving +2.04% from the previous trading session.
